Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr;9(2):87-91.
doi: 10.1136/flgastro-2016-100762. Epub 2017 Feb 22.

Practical guidance on the use of faecal calprotectin

Matthew J Brookes  1 , Simon Whitehead  2 , Daniel R Gaya  3 , Antony Barney Hawthorne  4
Affiliations
Review

Practical guidance on the use of faecal calprotectin

Matthew J Brookes et al. Frontline Gastroenterol. 2018 Apr.

Abstract

Differentiation between inflammatory bowel disease (IBD) and functional gut disorders, and the determination of mucosal disease activity in established cases of IBD remain the cornerstones of disease diagnosis and management. Non-invasive, accurate biomarkers of gut inflammation are needed due to the variability of symptoms, the inaccuracies of currently available blood markers and the cost and invasive nature of endoscopy. Numerous biomarkers have been used and/or considered with some in current use. This article reviews the current evidence base around the indications for using biomarkers and their limitations, with a particular focus on faecal calprotectin.

Keywords: CROHN'S DISEASE; IBD; STOOL MARKERS; ULCERATIVE COLITIS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: MJB has received honoraria for advisory board membership to Shield Pharma and Vifor Pharma. He has received grant support from Vifor Pharma. He has been supported for conference expenses by MSD, Vifor, AbbVie, Warner Chilcott and Allergan. None of these was directly related to the preparation of this work. DRG is funded by a Senior NRS Fellowship Award.

References

    1. Mowat C, Cole A, Windsor A, et al. . Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607. doi:10.1136/gut.2010.224154 - DOI - PubMed
    1. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterol 2011;140:1817–26. doi:10.1053/j.gastro.2010.11.058 - DOI - PMC - PubMed
    1. Menees SB, Powell C, Kurlander J, et al. . A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol 2015;110:444–54. doi:10.1038/ajg.2015.6 - DOI - PubMed
    1. Van de Logt F, Day AS. S100A12: a noninvasive marker of inflammation in inflammatory bowel disease. J Dig Dis 2013;14:62–7. doi:10.1111/1751-2980.12012 - DOI - PubMed
    1. Meijer B, Gearry RB, Day A. The role of s100A12 as a systemic marker of inflammation. Int J Inflamm 2012;2012:907078 doi:10.1155/2012/907078 - DOI - PMC - PubMed

LinkOut - more resources